Towards precision oncology in angiosarcomas using next generation “omic” technologies
Metrics: PDF 410 views | Full Text 843 views | ?
Grace Fangmin Tan1 and Jason Yongsheng Chan1,2
1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
2 Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore
|Jason Yongsheng Chan,||email:||firstname.lastname@example.org|
Keywords: rare cancer; single cell sequencing; chemoresistance; spatial transcriptomics
Received: March 31, 2021 Accepted: June 10, 2021 Published: September 14, 2021
Angiosarcomas are a group of aggressive tumors of vascular origin. Although thought to be a rare cancer constituting just 1–2% of all soft tissue sarcomas, recent observations suggest that angiosarcomas are more common amongst Asian populations as compared to the West, suggesting the possibility of distinct genetic or environmental triggers influencing its pathogenesis. Advances in genomic sequencing efforts have led to the discovery of ultraviolet mutation signatures and high tumor mutation burden as common features of angiosarcoma of the head and neck. In addition, multi-omic analyses integrated with clinical data identified 3 subtypes characterized by distinctive etiological and biological phenotypes, with potential implications on precision therapy. The systemic and local immune milieu, as well as the presence of “giant” tumor cells, was also recently demonstrated to influence clinical behavior and patient outcomes, further highlighting complexities of this disease. Improvements in next generation “omic”-based technologies are expected to improve our understanding of angiosarcoma and guide the development of precision oncology in this rare cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.